Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/25/2025

Hormone Therapy and Breast Cancer Risk

Introduction to Hormone Therapy and Breast Cancer Risk

  • The Women's Health Initiative (WHI) study showed that estrogen plus progestin therapy significantly increases breast cancer risk, with a 26% increased risk (HR 1.26; 95% CI, 1.00 to 1.59) in postmenopausal women 1
  • Hormone therapy is contraindicated in women with a history of breast cancer, including those with hormone receptor-negative disease, as recommended by the American College of Obstetricians and Gynecologists 1

Breast Cancer Risk with Different Types of Hormone Therapy

  • Synthetic progestins carry a higher breast cancer risk, while micronized progesterone appears significantly safer, with a lower risk of breast cancer compared to synthetic progestins (related to 1)
  • Natural progesterone is associated with significantly lower breast cancer risk compared to synthetic progestins, according to a meta-analysis (related to 1)
  • The American College of Obstetricians and Gynecologists recommends considering the use of micronized progesterone rather than synthetic progestins for hormone therapy (related to 1)
  • Estrogen-only therapy carries a lower breast cancer risk compared to combined estrogen-progestin therapy for postmenopausal women, particularly when using natural progesterone instead of synthetic progestins if a progestogen is required, as suggested by the American College of Physicians 2

Duration and Dose of Hormone Therapy

  • Risk increases with duration of use for combined estrogen-progestin therapy, with long-term users (>5 years) having a relative risk of 1.23 to 1.35 for breast cancer (related to 1)
  • The FDA recommends using the lowest effective dose for the shortest duration needed to minimize breast cancer risk (related to 1)
  • Short-term use of HRT (<5 years) carries less risk than long-term use, with a lower relative risk of breast cancer 3

Special Populations

  • Women with BRCA1/2 mutations should be counseled about the potential additional breast cancer risk with HRT, as recommended by the American College of Obstetricians and Gynecologists 4
  • Breast cancer risk with HRT is higher in older women, women with low BMI in menopause, and women with increased mammographic breast density (related to 1 and 4)

Monitoring and Screening

  • All women on hormone therapy should receive yearly breast examinations and perform monthly breast self-examinations, as recommended by the American College of Obstetricians and Gynecologists (related to 1 and 4)
  • Mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results, as recommended by the American College of Radiology (related to 1 and 4)
  • The Women's Health Initiative (WHI) study provides the strongest evidence regarding HRT and breast cancer risk, showing that estrogen-only therapy is associated with a statistically significant reduction in invasive breast cancer incidence compared to placebo (HR 0.77; 95% CI, 0.62 to 0.95), with an absolute risk reduction of 8 fewer cases per 10,000 person-years 2

Risks and Benefits

  • Combined estrogen-progestin therapy is associated with an increased risk of invasive breast cancer (HR 1.26; 95% CI, 1.00 to 1.59) 3, 2
  • The absolute increase in breast cancer cases with combined HRT is approximately 8 additional cases per 10,000 women-years 2
  • HRT decisions should also consider other risks, including cardiovascular disease, venous thromboembolism, and stroke, which are increased with HRT use 2, 5
  • For women without a uterus, estrogen-only therapy is preferred due to lower breast cancer risk, and the lowest effective dose should be used for the shortest duration needed 5
  • For women with an intact uterus who require progestogen, natural progesterone may be safer than synthetic progestins with respect to breast cancer risk 2